Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8⁺ T cell activation in the presence of adjuvant temozolomide.

ABSTRACT: In a two-stage phase II study, 24 patients with first diagnosis of glioblastoma (GBM) were treated with dendritic cell (DC) immunotherapy associated to standard radiochemotherapy with temozolomide (TMZ) followed by adjuvant TMZ. Three intradermal injections of mature DC loaded with autologous GBM lysate were administered before adjuvant TMZ, while 4 injections were performed during adjuvant TMZ. According to a two-stage Simon design, to proceed to the second stage progression-free survival (PFS) 12 months after surgery was expected in at least 8 cases enrolled in the first stage. Evidence of immune response and interaction with chemotherapy were investigated. After a median follow up of 17.4 months, 9 patients reached PFS12. In these patients (responders, 37.5%), DC vaccination induced a s

SUBMITTER: Pellegatta S 

PROVIDER: S-EPMC5889286 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature